NCT06742060 The Trend of Copeptin Levels and Its Clinical Value for Postoperative CDI in Pediatric Patients After NSI in ICU
| NCT ID | NCT06742060 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Hospital of Fudan University |
| Condition | Diabetes Insipidus, Neurohypophyseal |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-11-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-11-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Central diabetes insipidus (CDI),a disease caused by the decrease of AVP (a hormone involved in the control of water-electrolyte balance ) secretion and characerized by polyuria, is a common complication after neurosurgerical intervention and there is a lack of diagnostic criteria.Since the surgry casuses damage to patients' AVP-secreting neuronal cells, transient CDI (t-CDI) usually occurs 24-48h postoperatively and gradually resolves in about 10 days.However,permanent CDI (p-CDI) occurs in a small percentage of patients.Copeptin is a fragment of AVP, which has been shown to response the secretion of AVP.Multiple international studies have identified clinical applications for the use of copeptin to differentially diagnose adults with CDI , to assess electrolyte disturbances associated with AVP regulation, and to predict postoperative CDI after pituitary surgery.This study aims to investigate the trend of serum copeptin levels and its clinical value for postoperative CDI in pediatric patients after neurosurgerical intervention in ICU.
Eligibility Criteria
Inclusion Criteria: * Male and female,age ≥29 days and \<18 years * After neurosurgical intervention * The patient agrees to comply with the requirements of the program, including follow-up visits and other related matters Exclusion Criteria: * Structural diseases of the genitourinary system (with the possibility of nephrogenic diabetes insipidus) * Preoperative symptoms of diabetes insipidus * Diabetes mellitus (HbA1c \>8.5%) * Drugs causing excessive drinking and urination (e.g., sodium-glucose cotransporter-2 inhibitors and diuretics) * Lack of follow-up data after 3 months
Contact & Investigator
guoping Lu
PRINCIPAL INVESTIGATOR
Children's Hospital of Fudan University
Frequently Asked Questions
Who can join the NCT06742060 clinical trial?
This trial is open to participants of all sexes, aged 29 Days or older, up to 18 Years, studying Diabetes Insipidus, Neurohypophyseal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06742060 currently recruiting?
Yes, NCT06742060 is actively recruiting participants. Contact the research team at jinyi036@126.com for enrollment information.
Where is the NCT06742060 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06742060 clinical trial?
NCT06742060 is sponsored by Children's Hospital of Fudan University. The principal investigator is guoping Lu at Children's Hospital of Fudan University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.